[Medico-economic assessment of the therapeutic management of patients with hepatitis C].
OBJECTIVE
To present a review of the literature on the economic assessment of health care for hepatitis C virus infected patients.


METHODS
The identification of articles was based on Medline. A scale was used to compare the methodology and results of the economic evaluations.


RESULTS
The results emphasize the shortage of studies in the field of hepatitis C, and the inadequacy of epidemiological, clinical and economic data on hepatitis C virus infection, as well as of clinical research from an economic perspective.


CONCLUSIONS
To implement an efficient screening and health care policy, health care decision makers need criteria to evaluate the efficiency of treatment strategies for hepatitis C. Economic analyses could provide important information for the social debate on hepatitis treatment.
Loubière
S
S
INSERM U 379, Epidémiologie et Sciences Sociales Appliquées à l'Innovation Médicale, Marseille.
Rotily
M
M
Moatti
J P
JP
D000998:Antiviral Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000191:economics*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy / Q000191:economics; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D011788:Quality of Life; D013997:Time Factors
D000998:Antiviral Agents; D016898:Interferon-alpha